Pelthos Therapeutics Inc. (PTHS) shareholders
Close on Nov 17, 2026Market cap $26.19MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Ligand Pharmaceuticals Incorporated | 5,189,177 | 49.90% | 13D (active) amendment | Oct 30, 2026 |
| Alexandra Wood (Canada) Inc. | 574,187 | 9.53% | 13G (passive) | Dec 13, 2024 |
| Motif Pharmaceuticals Ltd. | 483,406 | 8.40% | 13G (passive) | Feb 21, 2024 |
| Boswell Prayer Ltd Joint filing with Rochelle Gross (8.20%) | 471,592 | 8.20% | 13G (passive) | Feb 21, 2024 |
| Aperture Healthcare Ventures Ltd. | 444,070 | 7.70% | 13G (passive) | Feb 21, 2024 |
| Benuvia Operations, LLC Joint filing with Darwin Richardson (6.70%) | 384,226 | 6.70% | 13G (passive) | Feb 21, 2024 |
| Maier Joshua Tarlow Joint filing with 3i, LP (9.90%), 3i Management LLC (9.90%) | 337,026 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| 3i Management LLC Joint filing with 3i, LP (9.90%), Maier Joshua Tarlow (9.90%) | 318,886 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| 3i, LP Joint filing with 3i Management LLC (9.90%), Maier Joshua Tarlow (9.90%) | 303,138 | 9.90% | 13G (passive) | Jul 1, 2025 |
| Marc Bistricer Joint filing with Murchinson Ltd. (9.10%) | 280,000 | 9.10% | 13G (passive) | Sep 30, 2025 |
| Neil Shahrestani Joint filing with Ikarian Capital, LLC (7.70%) | 256,598 | 7.70% | 13G (passive) amendment | Mar 31, 2026 |
| Ezra Friedberg | 250,121 | 8.30% | 13D (active) amendment | Jul 1, 2025 |
| Ikarian Capital, LLC Joint filing with Neil Shahrestani (6.10%) | 186,408 | 6.10% | 13G (passive) amendment | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PTHS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| AIGH Capital Management LLC | 329,098 | 8.60% | $9.30M | New | 0.59% |
| Murchinson Ltd. | 304,302 | 7.95% | $8.60M | +7,988 | 1.19% |
| Ikarian Capital, LLC | 256,598 | 6.70% | $7.25M | – | 0.78% |
| Boothbay Fund Management, LLC | 101,976 | 2.66% | $2.88M | +20,118 | 0.04% |
| Vanguard Capital Management LLC | 97,134 | 2.54% | $2.75M | +4,041 | 0.00% |
| Cantor Fitzgerald, L. P. | 76,246 | 1.99% | $2.15M | +34,823 | 0.01% |
| J. Goldman & Co LP | 38,075 | 0.99% | $1.08M | −12,340 | 0.03% |
| Diadema Partners LP | 24,773 | 0.65% | $700.09K | – | 0.09% |
| Wexford Capital LP | 22,364 | 0.58% | $632.01K | New | 0.08% |
| Knott David M Jr | 22,073 | 0.58% | $623.78K | +1,000 | 0.33% |
| Citadel Advisors LLC | 15,046 | 0.39% | $425.20K | New | 0.00% |
| Geode Capital Management, LLC | 14,650 | 0.38% | $414.01K | −640 | 0.00% |
| Pale Fire Capital SE | 12,919 | 0.34% | $365.09K | – | 0.03% |
| 1492 Capital Management LLC | 10,380 | 0.27% | $293.34K | New | 0.09% |
| Vanguard Fiduciary Trust Co | 9,873 | 0.26% | $279.01K | +56 | 0.00% |
| State Street Corp | 9,800 | 0.26% | $276.95K | New | 0.00% |
| Persistent Asset Partners Ltd | 6,007 | 0.16% | $169.76K | – | 0.05% |
| BlackRock, Inc. | 5,324 | 0.14% | $150.46K | New | 0.00% |
| UBS Group AG | 2,217 | 0.06% | $62.65K | +1,453 | 0.00% |
| China Universal Asset Management Co., Ltd. | 2,160 | 0.06% | $61.04K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 24 | 1M | 35.6% | 10 / 7 | 2 / 3 | 0M | 0M |
| Q1 2026 | 17 | 1M | 23.8% | 5 / 8 | 2 / 2 | 0M | 0M |
| Q4 2025 | 15 | 1M | 23.5% | 4 / 10 | 0 / 3 | 0M | 0M |
| Q3 2025 | 14 | 0M | 12.1% | 14 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
9 funds held PTHS in Q2 2026, 87% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PTHS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 78,008 | 2.04% | $2.20M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 16,128 | 0.42% | $455.78K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 7,464 | 0.19% | $197.57K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 4,991 | 0.13% | $141.05K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 2,052 | 0.05% | $54.32K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 1,972 | 0.05% | $52.20K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 1,818 | 0.05% | $51.38K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 1,180 | 0.03% | $33.35K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 333 | 0.01% | $9.41K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Scott M. Plesha | CEO and President, Director | 83,678 | 2.19% | Apr 1, 2026 |
| Knuettel Francis II | CFO, Treas & Secty | 40,841 | 1.07% | May 26, 2026 |
| John M. Gay | Chief Financial Officer | 30,518 | 0.80% | Apr 20, 2026 |
| Sai Rangarao | Chief Commercial Officer | 30,518 | 0.80% | Apr 1, 2026 |
| Matthew Pauls | Director | 13,578 | 0.35% | Oct 6, 2026 |
| Ezra M. Friedberg | Director | 202,556 | 5.29% | Oct 6, 2026 |
| Peter Greenleaf | Director | 23,087 | 0.60% | Oct 6, 2026 |
| Todd C. Davis | Director | 1,575,331 | 41.15% | Jun 15, 2026 |
| Richard Malamut | Director | 28,462 | 0.74% | Apr 6, 2026 |
| Richard B. Baxter | Director | 19,108 | 0.50% | Apr 1, 2026 |
| Andrew J. Einhorn | Director | 12,000 | 0.31% | Dec 29, 2025 |
| Pharmaceuticals Inc Ligand | Director, 10% owner | 1,500,000 | 39.18% | Dec 19, 2025 |
| Chia-Lin Simmons | Director | – | – | Apr 15, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Peter Greenleaf Director | Oct 2, 2026 | Sale(10b5-1 plan) | −797 | $21.17 | $16.87K | 23,087 |
| Ezra M. Friedberg Director | Oct 2, 2026 | Sale(10b5-1 plan) | −558 | $20.72 | $11.56K | 80,484 |
| Matthew Pauls Director | Oct 2, 2026 | Sale(10b5-1 plan) | −786 | $21.00 | $16.51K | 13,578 |
| Matthew Pauls Director | Jul 2, 2026 | Sale(10b5-1 plan) | −692 | $26.00 | $17.99K | 14,458 |
| Matthew Pauls Director | Jul 2, 2026 | Sale(10b5-1 plan) | −94 | $27.36 | $2.57K | 14,364 |
| Ezra M. Friedberg Director | Jul 2, 2026 | Sale(10b5-1 plan) | −24 | $27.33 | $656 | 81,042 |
| Ezra M. Friedberg Director | Jul 2, 2026 | Sale(10b5-1 plan) | −534 | $26.03 | $13.90K | 81,066 |
| Peter Greenleaf Director | Jul 2, 2026 | Sale(10b5-1 plan) | −85 | $27.27 | $2.32K | 23,884 |
| Peter Greenleaf Director | Jul 2, 2026 | Sale(10b5-1 plan) | −712 | $26.00 | $18.51K | 23,969 |
| Ezra M. Friedberg Director | Jun 15, 2026 | Sale(10b5-1 plan) | −59 | $27.94 | $1.65K | 81,600 |
| Ezra M. Friedberg Director | Jun 15, 2026 | Sale(10b5-1 plan) | −224 | $27.12 | $6.07K | 81,659 |
| Todd C. Davis Director | Jun 11, 2026 | Buy | +35,445 | $27.80 | $985.37K | 75,331 |
| Todd C. Davis Director | Jun 11, 2026 | Buy | +503 | $28.73 | $14.45K | 75,834 |
| Knuettel Francis II CFO, Treas & Secty | May 22, 2026 | Returned to company | −13,947 | – | – | 19,525 |
| Knuettel Francis II CFO, Treas & Secty | May 22, 2026 | Sale | −1,500 | $26.84 | $40.26K | 11,316 |
| Ezra M. Friedberg Director | May 14, 2026 | Tax withholding | −144 | $27.01 | $3.89K | 81,883 |
| Richard Malamut Director | Apr 2, 2026 | Sale(10b5-1 plan) | −280 | $21.36 | $5.98K | 27,422 |
| Richard Malamut Director | Apr 2, 2026 | Sale(10b5-1 plan) | −310 | $20.51 | $6.36K | 27,702 |
| Matthew Pauls Director | Apr 2, 2026 | Sale(10b5-1 plan) | −415 | $20.52 | $8.52K | 15,521 |
| Matthew Pauls Director | Apr 2, 2026 | Sale(10b5-1 plan) | −371 | $21.36 | $7.92K | 15,150 |
| Ezra M. Friedberg Director | Apr 2, 2026 | Sale(10b5-1 plan) | −265 | $21.36 | $5.66K | 82,027 |
| Ezra M. Friedberg Director | Apr 2, 2026 | Sale(10b5-1 plan) | −293 | $20.51 | $6.01K | 82,292 |
| Peter Greenleaf Director | Apr 2, 2026 | Sale(10b5-1 plan) | −377 | $21.36 | $8.05K | 24,681 |
| Peter Greenleaf Director | Apr 2, 2026 | Sale(10b5-1 plan) | −420 | $20.52 | $8.62K | 25,058 |
| Andrew J. Einhorn Director | Dec 23, 2025 | Award | +12,000 | – | – | 12,000 |
| Matthew Pauls Director | Dec 10, 2025 | Gift | −9,542 | – | – | 1,074 |
| Ezra M. Friedberg Director | Nov 25, 2025 | Sale | −2,000 | $28.14 | $56.28K | 32,001 |
| Ezra M. Friedberg Director | Nov 25, 2025 | Sale | −1 | $28.50 | $29 | 32,000 |
| Ezra M. Friedberg Director | Nov 25, 2025 | Sale | −2,000 | $28.01 | $56.02K | 30,000 |
| Ezra M. Friedberg Director | Nov 25, 2025 | Sale | −5,999 | $28.00 | $167.97K | 34,001 |
| Richard Malamut Director | Nov 13, 2025 | Award | +2,454 | – | – | 8,904 |
| Matthew Pauls Director | Oct 2, 2025 | Option exercise | +2,123 | – | – | 10,616 |
| Knuettel Francis II CFO, Treas & Secty | Jul 2, 2025 | Award | +33,472 | – | – | 33,472 |
| Sai Rangarao Chief Commercial Officer | Jul 2, 2025 | Award | +30,518 | – | – | 30,518 |
| Richard B. Baxter Director | Jul 2, 2025 | Award | +19,108 | – | – | 19,108 |
| Scott M. Plesha CEO and President, Director | Jul 2, 2025 | Award | +83,678 | – | – | 83,678 |
| Richard Malamut Director | Jul 2, 2025 | Award | +19,108 | – | – | 28,012 |
| Ezra M. Friedberg Director | Jul 2, 2025 | Award | +19,108 | – | – | 82,585 |
| Matthew Pauls Director | Jul 2, 2025 | Award | +25,478 | – | – | 25,478 |
| Peter Greenleaf Director | Jul 2, 2025 | Award | +25,478 | – | – | 25,478 |
| Todd C. Davis Director | Jul 2, 2025 | Award | +19,108 | – | – | 39,886 |
| Matthew Pauls Director | Jul 2, 2025 | Option exercise | +8,493 | – | – | 8,493 |
| Knuettel Francis II Chief Financial Officer | Jul 1, 2025 | Conversion | +10,000 | $10.00 | $100.00K | 10,000 |
| Pharmaceuticals Inc Ligand 10% owner | Jul 1, 2025 | Conversion | +1,500,000 | $10.00 | $15.00M | 1,500,000 |
| Todd C. Davis Director, 10% owner | Jul 1, 2025 | Conversion | +1,500,000 | $10.00 | $15.00M | 1,500,000 |
| Ezra M. Friedberg Director | Jul 1, 2025 | Conversion | +40,000 | $10.00 | $400.00K | 40,000 |
| Ezra M. Friedberg Director | Jul 1, 2025 | Conversion | +40,000 | $10.00 | $400.00K | 40,000 |
| Ezra M. Friedberg Director | Nov 13, 2024 | Award | +2,454 | – | – | 63,477 |
| Todd C. Davis Director | Nov 13, 2024 | Award | +4,961 | – | – | 20,778 |
| Knuettel Francis II CEO, Pres., CFO, Treas & Secty | Sep 13, 2024 | Buy | +3,500 | $0.97 | $3.40K | 547,710 |
| Richard Malamut Director | Sep 12, 2024 | Buy | +10,400 | $0.94 | $9.78K | 91,565 |
| Knuettel Francis II CEO, Pres., CFO, Treas & Secty | Sep 12, 2024 | Buy | +1,700 | $0.97 | $1.65K | 544,210 |
| Knuettel Francis II CEO, Pres., CFO, Treas & Secty | Sep 11, 2024 | Buy | +5,500 | $0.94 | $5.17K | 542,510 |
| Knuettel Francis II CEO, Pres., CFO, Treas & Secty | Sep 10, 2024 | Buy | +6,500 | $0.89 | $5.79K | 537,010 |
| Knuettel Francis II CEO, Pres., CFO Treas & Secty | Jun 28, 2024 | Gift | −15,000 | – | – | 515,510 |
| Knuettel Francis II CEO, Pres., CFO Treas & Secty | Jun 28, 2024 | Gift | −5,000 | – | – | 530,510 |
| Richard Malamut Director | Jun 14, 2024 | Award | +6,450 | – | – | 6,450 |
| Ezra M. Friedberg Director | Jun 14, 2024 | Award | +6,450 | – | – | 61,023 |
| Todd C. Davis Director | Jun 14, 2024 | Award | +12,900 | – | – | 15,817 |
| Ezra M. Friedberg Director | Feb 21, 2024 | Buy | +16,667 | $6.00 | $100.00K | 545,721 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Pelthos Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,230 shares on Oct 14, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Knuettel Francis II Officer | May 22, 2026 | 1,720 | $46.63K | May 22, 2026 | Market |
See a number that looks wrong?